Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [1]. Core Views - The clinical CRO industry is experiencing a recovery, with increasing demand driven by the global rise in innovative drug financing and the expansion of clinical trial outsourcing. The company is expected to benefit from this trend, with a significant increase in new orders and market share [8]. - The company has established itself as a leader in the clinical CRO market in China, with its market share rising from 8.7% in 2019 to 12.8% in 2023. This growth is attributed to the optimization of supply and the company's strong competitive position [8]. - The company's revenue and profit forecasts indicate a recovery, with expected revenues of 71.29 billion yuan in 2025, 80.19 billion yuan in 2026, and 93.27 billion yuan in 2027, alongside a substantial increase in net profit [8]. Summary by Sections Company Overview - Founded in 2004, the company has grown to become a leading clinical CRO in China, providing comprehensive services for the biopharmaceutical industry through self-built and acquired networks [14]. - The company's ownership structure is stable, with key founders holding significant shares and a management team experienced in top-tier biopharmaceutical companies [15]. Financial Analysis - The company has experienced revenue growth from 254 million yuan in 2012 to 6.603 billion yuan in 2024, with a compound annual growth rate (CAGR) of 28.5%. However, growth has slowed in 2023 and 2024 due to market conditions [19]. - The company’s gross margin has faced pressure, but a recovery is anticipated in 2026 as low-priced orders are cleared and new orders increase [22]. Industry Outlook - The global demand for CRO services is expected to grow, with the penetration rate of outsourced pharmaceutical R&D projected to exceed 50% by 2024 and reach approximately 65% by 2033 [43]. - The number of CRO companies in China has decreased significantly due to market consolidation, enhancing the competitive landscape for leading firms like the company [52]. Business Segments - The company operates primarily in two segments: Clinical Trial Technical Services (CTS) and Clinical Trial Related Services and Laboratory Services. CTS is the cornerstone of the business, covering all phases of clinical trials [54]. - The company has a strong international presence, with operations in 33 countries and a growing number of overseas projects, reflecting its commitment to global expansion [63].

证券研究报告：医药生物 | 公司点评报告 股票投资评级 Q3 收入增速稳定，毛利率显著回暖 ⚫ 事件 买入|首次覆盖 个股表现 -3% 10% 23% 36% 49% 62% 75% 88% 101% 114% 2025-01 2025-03 2025-06 2025-08 2025-10 2026-01 普蕊斯 医药生物 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 56.80 | | --- | --- | | 总股本/流通股本（亿股）0.79 / 0.75 | | | 总市值/流通市值（亿元）45 / 43 | | | 52 周内最高/最低价 | 56.80 / 24.84 | | 资产负债率(%) | 17.9% | | 市盈率 | 42.07 | | 第一大股东 | 石河子市玺泰股权投资 | | 合伙企业(有限合伙) | | 研究所 分析师:盛丽华 SAC 登记编号:S1340525060001 Email:shenglihua@cnpsec.com 分析师:陈灿 SAC 登记编号:S1340525070001 Email:chencan@cnpsec.com 普蕊斯(30 ...

Core Insights - The Chinese biopharmaceutical industry is showing signs of recovery in 2025, with increased license-out transactions, a rebound in primary market financing, and the return of cornerstone investors in Hong Kong biotech IPOs, suggesting a shift from a prolonged downturn to a more normalized state [1][2][4] Group 1: Market Recovery and Trends - The market is transitioning from an "extreme compression" phase to a "relatively normal" state, indicating a quality recovery rather than a full-blown boom [2][4] - The overall pharmaceutical industry saw a 16.72% increase from early 2025 to November, outperforming the CSI 300 index by 1.68 percentage points, driven by breakthroughs in innovative drugs [2][3] - License-out transactions in the innovative drug sector reached $93.7 billion in the first three quarters of 2025, a 64% increase year-on-year, surpassing the total financing amount in the primary market for the first time [3][4] Group 2: Structural Changes and Investment Logic - The core driving forces behind the industry's progress are structural changes rather than short-term stimuli, with a focus on rational project selection and differentiation in product pipelines [2][5] - Investors are increasingly prioritizing clinical data certainty, product differentiation, and global commercialization potential over chasing trends [2][4] - The competitive edge of Chinese innovative drugs has significantly improved, leading to increased cross-border licensing collaborations and the emergence of new cross-border companies [4][5] Group 3: Challenges and Future Indicators - Despite positive trends, challenges such as global interest rate changes, geopolitical uncertainties, and ongoing pressures on domestic healthcare payments remain [4][5] - Key indicators for assessing the sustainability of the recovery include the continued occurrence of high-quality license-out transactions and the ability of Hong Kong to nurture companies with solid data and commercialization capabilities [5][12] Group 4: Global Integration and Market Dynamics - The integration of Chinese innovative drugs into the global pharmaceutical ecosystem is evident, with cross-border collaborations becoming crucial for value realization [11][12] - The return of overseas investors to Hong Kong biotech IPOs reflects a long-term rebuilding of confidence, contingent on companies having globally competitive product pipelines and clear clinical data timelines [11][12] - The differentiation in market dynamics necessitates careful selection of IPO venues based on pipeline stages, funding needs, and adaptability to market rules [12][13] Group 5: Strategic Considerations for Biotech Companies - For small and medium-sized biotech firms, balancing global R&D and commercialization with solidifying the domestic market is a critical challenge [13][14] - A phased globalization approach is recommended, where early R&D aligns with international standards while domestic commercialization focuses on core areas to validate product value [13][14] - The industry's evolution emphasizes quality, differentiation, and global capability, with the 2025 recovery seen as a return to normalcy after a period of structural advantage accumulation [14]

Core Insights - The global and US innovative drug VC&PE financing amounts are expected to grow by 1.93% and 5.29% respectively in 2024, indicating a recovery in the innovative drug financing environment [1] - The demand for research and development in fields such as peptides and ADCs is strong, leading to an increase in outsourcing needs in these areas [1][2] Macro Perspective - The global innovative drug financing environment is recovering, with significant growth in the demand for innovative research in specific fields like peptides and ADCs, which is expected to enhance the CXO industry's outlook [1] - According to Crunchbase, the VC&PE financing for innovative drugs in 2024 shows positive growth, marking an improvement in the financing environment [1] Micro Perspective - CXO listed companies are seeing a recovery in new orders, with many companies like WuXi AppTec, WuXi Biologics, and others reporting a year-on-year increase of over 20% in new orders [3] - The production capacity of domestic CXO companies is mature, ensuring timely delivery of orders, which is expected to lead to double-digit revenue growth for several companies in 2025 [3] Target Companies - Recommended companies to watch include WuXi AppTec (603259.SH, 02359), WuXi Biologics (02269), WuXi AppTec (02268), Kelun Pharmaceutical (002821.SZ, 06821), and others [4]